- Genentech's Columvi shows a 40% survival benefit in a two-year follow-up for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- 89% of patients who fully responded to Columvi therapy are alive after one year.
- Columvi combination approved in over 30 countries for DLBCL patients not suited for stem cell transplant.
Genentech, a member of the Roche Group (RHHBY, Financial), has announced promising two-year follow-up results from the pivotal Phase III STARGLO study. Data reveal a 40% improvement in overall survival (OS) for patients treated with Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx), as compared to 13.5 months for those treated with Rituxan® (rituximab) plus GemOx (R-GemOx).
The updated results highlight Columvi's significant efficacy for individuals with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant (ASCT). A median follow-up of 24.7 months indicates Columvi's potential for extending patient survival and providing a needed treatment option. Among patients whose cancer fully responded to Columvi, 89% were alive one year post-treatment, with 82% maintaining remission.
Columvi is part of Genentech's leading CD20xCD3 bispecific antibody program and is approved in over 30 countries, including the EU, for patients with relapsed or refractory DLBCL not eligible for transplant. The findings, which will be presented at the American Society of Clinical Oncology (ASCO) meeting, bolster the case for Columvi as a pivotal treatment in managing aggressive lymphomas and improving long-term outcomes.
